|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CBWD7 |
Gene summary for CBWD7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CBWD7 | Gene ID | 644019 |
| Gene name | COBW domain containing 6 | |
| Gene Alias | CBWD7 | |
| Cytomap | 9p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q4V339 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 644019 | CBWD7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.09e-36 | 6.40e-01 | 0.294 |
| 644019 | CBWD7 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.71e-18 | 1.81e+00 | 0.3487 |
| 644019 | CBWD7 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.79e-34 | 9.68e-01 | 0.281 |
| 644019 | CBWD7 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.21e-39 | 8.32e-01 | 0.3859 |
| 644019 | CBWD7 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.98e-12 | 4.83e-01 | 0.2585 |
| 644019 | CBWD7 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.58e-25 | 4.63e-01 | 0.3005 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CBWD7 | SNV | Missense_Mutation | novel | c.305A>G | p.Glu102Gly | p.E102G | A6NM15,Q4V339 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.311N>A | p.Arg104Lys | p.R104K | A6NM15,Q4V339 | protein_coding | tolerated(0.52) | possibly_damaging(0.626) | TCGA-AC-A3W7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.305N>G | p.Glu102Gly | p.E102G | A6NM15,Q4V339 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.305N>G | p.Glu102Gly | p.E102G | A6NM15,Q4V339 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.305N>G | p.Glu102Gly | p.E102G | A6NM15,Q4V339 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-E2-A1L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.457N>A | p.Asp153Asn | p.D153N | A6NM15,Q4V339 | protein_coding | deleterious(0.01) | possibly_damaging(0.651) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.272N>A | p.Ser91Asn | p.S91N | A6NM15,Q4V339 | protein_coding | tolerated(0.21) | possibly_damaging(0.74) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.1118N>G | p.Phe373Cys | p.F373C | A6NM15,Q4V339 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CBWD7 | SNV | Missense_Mutation | novel | c.431N>A | p.Gly144Asp | p.G144D | A6NM15,Q4V339 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-3901-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CBWD7 | SNV | Missense_Mutation | rs753945418 | c.853N>A | p.Ala285Thr | p.A285T | A6NM15,Q4V339 | protein_coding | tolerated(0.54) | benign(0.009) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |